Trastuzumab Antibody Kit ELISA

N° du produit ABIN4886400

Ce kit ELISA Colorimetric est conçu pour la mesure quantitative de Humain, Souris et Rat Trastuzumab Antibody.

Aperçu rapide pour Trastuzumab Antibody Kit ELISA (ABIN4886400)

Antigène: Trastuzumab Antibody

Reactivité: Humain, Souris, Rat

Méthode de détection: Colorimetric

Type de méthode: Bridging ELISA

Gamme de detection: 31.25-125 ng/mL

Application: ELISA

Type d'échantillon: Plasma, Serum

Détail du produit Trastuzumab Antibody Kit ELISA

Seuil minimal de détection: 31.25 ng/mL

Fonction: Quantification of antibodies to Trastuzumab

Analytical Method: Quantitative

Specificité: Anti-Trastuzumab antibodies

Attributs du produit: This immunogenicity assay employs the bridging ELISA technique.

Ingrédients: Coated microtiter plate, 96 wells
QC samples - 4x50ul
10X wash buffer - 25ml
Assay buffer - 50ml
1000X secondary antibody - 17ul
1000X detection reagent - 17ul
TMB - 12ml
TMB stop solution - 12ml
Plate sealers - 3

Matériel non inclus: Precision pipettes calibrated to deliver 5-1000μL
Multi-channel pipette calibrated to deliver 50-200μL
Plate shaker
Disposable tips
Vortex-Mixer
Distilled or de-ionized water
Microplate reader capable of reading 450nm with background subtrac

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Volume d'échantillon: 15 μL

Durée du test: 3.5 h

Plaque: Pre-coated

Protocole: The Trastuzumab immunogenicity assay employs the bridging ELISA technique. A precoated 96 well capture antibody plate is provided. Quality control and test samples are pipetted into the appropriate wells. Anti-Trastuzumab present in biological matrices binds the immobilized capture antibody. After washing away any unbound substances, secondary antibody is added to the wells and after a final wash a detection reagent is added. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of anti-Trastuzumab present in test samples. Four levels of QC samples give a qualitative reference signal which can be used to determine the level (High, Medium, Low, Negative) of anti-Trastuzumab antibody in the unknown samples.

Préparation des réactifs:

Prepare only the appropriate amount of required reagent on the day of use. Store all reagents as per instructions stated on the label. 1. Wash Buffer (1X) Preparation: Dilute wash buffer concentrate with ultra-pure water 1/10 before use (for example add 2 mL concentrate to 18 mL ultra-pure water). Mix well. 2. Secondary antibody (1X) Preparation: Dilute secondary antibody with assay buffer 1/1000 before use (for examples add 12 μL concentrate to 12 mL of assay buffer). Mix well. 3. Detection Reagent (1X) Preparation: Dilute detection reagent with assay buffer 1/1000 before use (for example add 12 μL concentrate to 12 mL of assay buffer). Mix well.

Prélèvement de l'échantillon: This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20 °C for up to 1 year.

Préparation de l'échantillon:

Dilute QC samples and test samples 1/10 with assay buffer (for example add 30μL of prepared calibrator or sample to 270μL of assay buffer). Mix well. Do not store diluted samples. If test samples are out of range, then they may be further diluted.

Procédure de l'essai:

This immunogenicity assay employs the bridging ELISA technique. Capture antibody is precoated onto a 96 well microplate. Quality control and test samples are pipetted into the appropriate wells. AntiTrastuzumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, secondary antibody is added to the wells and after a final wash a detection reagent is added. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of anti-Trastuzumab present in test samples. Three levels of QC samples give a qualitative reference signal which can be used to determine the level of anti-Trastuzumab antibody in the unknown samples. The color development is stopped and the intensity of the color is measured.

Calcul des résultats:

1. Because anti-drug antibodies will vary in terms of affinity and concentration, this assay provides a qualitative readout. As such the user should use the comparable positive controls when comparing interassay results. The provided controls are tested for comparability between lots and can be traced. 2. The anti-drug antibody titers in the test samples will fall in the range of high, medium, low or negative. We recommend each lab develop their own statistical cutpoint using methodologies as described by G. Shankar, et al. (2008). (Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharmaceutical and Biomedical Analysis 48:1267-1281). 3. Any sample undiluted or diluted still reading greater than the highest standard should be diluted appropriately with assay buffer and retested. If the samples have been diluted, the concentration determined from the standard curve must be multiplied by the dilution factor.

Précision du teste: Intra-assay precision: < 10%
Inter-assay precision: < 10%

Restrictions: For Research Use only

Stockage

Agent conservateur: Without preservative

Précaution d'utilisation: Read manual completely before beginning

Stock: -20 °C

Stockage commentaire: Store kit components at -20°C unless specified otherwise. DO NOT USE past kit expiration date. Some vials contain a small amount of reagents. Spin tubes on pulse setting prior to opening.

Date de péremption: 12 months

Détail du antigène

Antigène: Trastuzumab Antibody

Classe de substances: Antibody

Sujet: Trastuzumab (Herceptin® ) is a humanized recombinant monoclonal antibody used for the treatment of primary breast cancers overexpressing human epidermal growth factor 2 (HER2). HER2 protein is overexpressed in 25-30 % of breast cancers.

ID gène: 2064